The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial decr